Literature DB >> 28802057

High-mobility group box 1 released by autophagic cancer-associated fibroblasts maintains the stemness of luminal breast cancer cells.

Xi-Long Zhao1, Yong Lin1, Jun Jiang2, Zhuo Tang1, Shuai Yang1, Lu Lu1, Yan Liang1,2, Xue Liu1, Jiao Tan1, Xu-Gang Hu1, Qin Niu1, Wen-Juan Fu1, Ze-Xuan Yan1, De-Yu Guo1, Yi-Fang Ping1, Ji Ming Wang3, Xia Zhang1, Hsiang-Fu Kung1, Xiu-Wu Bian1, Xiao-Hong Yao1.   

Abstract

Cancer stem cells/cancer-initiating cells (CICs) and their microenvironmental niche play a vital role in malignant tumour recurrence and metastasis. Cancer-associated fibroblasts (CAFs) are major components of the niche of breast cancer-initiating cells (BCICs), and their interactions may profoundly affect breast cancer progression. Autophagy has been considered to be a critical process for CIC maintenance, but whether it is involved in the cross-talk between CAFs and CICs to affect tumourigenesis and pathological significance has not been determined. In this study, we found that the presence of CAFs containing high levels of microtubule-associated protein 1 light chain 3 (LC3II), a marker of autophagosomes, was associated with more aggressive luminal human breast cancer. CAFs in human luminal breast cancer tissues with high autophagy activity enriched BCICs with increased tumourigenicity. Mechanistically, autophagic CAFs released high-mobility group box 1 (HMGB1), which activated its receptor, Toll-like receptor (TLR) 4, expressed by luminal breast cancer cells, to enhance their stemness and tumourigenicity. Furthermore, immunohistochemistry of 180 luminal breast cancers revealed that high LC3II/TLR4 levels predicted an increased relapse rate and a poorer prognosis. Our findings demonstrate that autophagic CAFs play a critical role in promoting the progression of luminal breast cancer through an HMGB1-TLR4 axis, and that both autophagy in CAFs and TLR4 on breast cancer cells constitute potential therapeutic targets.
Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  Toll-like receptor 4 (TLR4); autophagy; breast cancer-initiating cell (BCIC); cancer-associated fibroblast (CAF); high-mobility group box 1 (HMGB1)

Mesh:

Substances:

Year:  2017        PMID: 28802057      PMCID: PMC8171497          DOI: 10.1002/path.4958

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  52 in total

1.  In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells.

Authors:  Gabriela Dontu; Wissam M Abdallah; Jessica M Foley; Kyle W Jackson; Michael F Clarke; Mari J Kawamura; Max S Wicha
Journal:  Genes Dev       Date:  2003-05-15       Impact factor: 11.361

Review 2.  Deconvoluting the context-dependent role for autophagy in cancer.

Authors:  Eileen White
Journal:  Nat Rev Cancer       Date:  2012-04-26       Impact factor: 60.716

3.  Inhibition of autophagy as a new means of improving chemotherapy efficiency in high-LC3B triple-negative breast cancers.

Authors:  Sylvain Lefort; Carine Joffre; Yann Kieffer; Anne-Marie Givel; Brigitte Bourachot; Giulia Zago; Ivan Bieche; Thierry Dubois; Didier Meseure; Anne Vincent-Salomon; Jacques Camonis; Fatima Mechta-Grigoriou
Journal:  Autophagy       Date:  2014       Impact factor: 16.016

4.  TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules.

Authors:  Naoko Matsunaga; Noboru Tsuchimori; Tatsumi Matsumoto; Masayuki Ii
Journal:  Mol Pharmacol       Date:  2010-09-29       Impact factor: 4.436

5.  High-mobility group box 1 up-regulates aquaporin 4 expression via microglia-astrocyte interaction.

Authors:  Masatoshi Ohnishi; Ayaka Monda; Ryoko Takemoto; Yukina Fujimoto; Mitsumasa Sugitani; Takahiro Iwamura; Takashi Hiroyasu; Atsuko Inoue
Journal:  Neurochem Int       Date:  2014-06-02       Impact factor: 3.921

6.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.

Authors:  Christophe Ginestier; Min Hee Hur; Emmanuelle Charafe-Jauffret; Florence Monville; Julie Dutcher; Marty Brown; Jocelyne Jacquemier; Patrice Viens; Celina G Kleer; Suling Liu; Anne Schott; Dan Hayes; Daniel Birnbaum; Max S Wicha; Gabriela Dontu
Journal:  Cell Stem Cell       Date:  2007-11       Impact factor: 24.633

7.  Curcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNA.

Authors:  Carla Kantara; Malaney O'Connell; Shubhashish Sarkar; Stephanie Moya; Robert Ullrich; Pomila Singh
Journal:  Cancer Res       Date:  2014-03-13       Impact factor: 12.701

8.  Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE.

Authors:  Jane Tian; Ana Maria Avalos; Su-Yau Mao; Bo Chen; Kannaki Senthil; Herren Wu; Peggy Parroche; Stacey Drabic; Douglas Golenbock; Cherilyn Sirois; Jing Hua; Ling Ling An; Laurent Audoly; Greg La Rosa; Angelika Bierhaus; Peter Naworth; Ann Marshak-Rothstein; Mary K Crow; Katherine A Fitzgerald; Eicke Latz; Peter A Kiener; Anthony J Coyle
Journal:  Nat Immunol       Date:  2007-04-08       Impact factor: 25.606

9.  Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities.

Authors:  Luca Mollica; Francesco De Marchis; Andrea Spitaleri; Corrado Dallacosta; Danilo Pennacchini; Moreno Zamai; Alessandra Agresti; Lisa Trisciuoglio; Giovanna Musco; Marco E Bianchi
Journal:  Chem Biol       Date:  2007-04

10.  Low Dose, Low Cost Estradiol Pellets Can Support MCF-7 Tumour Growth in Nude Mice without Bladder Symptoms.

Authors:  Genevieve Dall; Jessica Vieusseux; Ashleigh Unsworth; Robin Anderson; Kara Britt
Journal:  J Cancer       Date:  2015-10-29       Impact factor: 4.207

View more
  37 in total

Review 1.  Targeting the tumour stroma to improve cancer therapy.

Authors:  Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta
Journal:  Nat Rev Clin Oncol       Date:  2018-06       Impact factor: 66.675

2.  Cancer-associated fibroblasts promote colorectal cancer progression by secreting CLEC3B.

Authors:  Hui-Fang Zhu; Xu-Hui Zhang; Chuan-Sha Gu; Yan Zhong; Ting Long; Yi-Dan Ma; Zhi-Yan Hu; Zu-Guo Li; Xiao-Yan Wang
Journal:  Cancer Biol Ther       Date:  2019-03-20       Impact factor: 4.742

Review 3.  Autophagy-dependent secretion: mechanism, factors secreted, and disease implications.

Authors:  Jacob New; Sufi Mary Thomas
Journal:  Autophagy       Date:  2019-04-14       Impact factor: 16.016

Review 4.  Tumor microenvironment promotes breast cancer chemoresistance.

Authors:  Umar Mehraj; Abid Hamid Dar; Nissar A Wani; Manzoor A Mir
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-09       Impact factor: 3.333

5.  MIR93 (microRNA -93) regulates tumorigenicity and therapy response of glioblastoma by targeting autophagy.

Authors:  Tianzhi Huang; Xuechao Wan; Angel A Alvarez; C David James; Xiao Song; Yongyong Yang; Namratha Sastry; Ichiro Nakano; Erik P Sulman; Bo Hu; Shi-Yuan Cheng
Journal:  Autophagy       Date:  2019-01-31       Impact factor: 16.016

Review 6.  Therapeutic targeting of the crosstalk between cancer-associated fibroblasts and cancer stem cells.

Authors:  Tu-Xiong Huang; Xin-Yuan Guan; Li Fu
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

Review 7.  Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment.

Authors:  Luke Bu; Hideo Baba; Naoya Yoshida; Keisuke Miyake; Tadahito Yasuda; Tomoyuki Uchihara; Patrick Tan; Takatsugu Ishimoto
Journal:  Oncogene       Date:  2019-02-28       Impact factor: 9.867

Review 8.  Role of lysosomes in physiological activities, diseases, and therapy.

Authors:  Ziqi Zhang; Pengfei Yue; Tianqi Lu; Yang Wang; Yuquan Wei; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2021-05-14       Impact factor: 17.388

Review 9.  Cell death in the gut epithelium and implications for chronic inflammation.

Authors:  Jay V Patankar; Christoph Becker
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-07-10       Impact factor: 46.802

Review 10.  Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer.

Authors:  Fanglong Wu; Jin Yang; Junjiang Liu; Ye Wang; Jingtian Mu; Qingxiang Zeng; Shuzhi Deng; Hongmei Zhou
Journal:  Signal Transduct Target Ther       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.